{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T18:49:26Z","timestamp":1774118966435,"version":"3.50.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,12,9]],"date-time":"2011-12-09T00:00:00Z","timestamp":1323388800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Tumor Biol."],"published-print":{"date-parts":[[2012,4]]},"DOI":"10.1007\/s13277-011-0275-1","type":"journal-article","created":{"date-parts":[[2011,12,8]],"date-time":"2011-12-08T06:31:37Z","timestamp":1323325897000},"page":"463-474","source":"Crossref","is-referenced-by-count":45,"title":["Utility of serum tumor markers as an aid in the differential diagnosis of patients with clinical suspicion of cancer and in patients with cancer of unknown primary site"],"prefix":"10.1007","volume":"33","author":[{"given":"Rafael","family":"Molina","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Bosch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep M.","family":"Auge","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xavier","family":"Filella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 M.","family":"Escudero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00edctor","family":"Molina","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manel","family":"Sol\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"L\u00f3pez-Soto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,12,9]]},"reference":[{"key":"275_CR1","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1146\/annurev.publhealth.22.1.91","volume":"22","author":"ML Brown","year":"2001","unstructured":"Brown ML, Lipscomb J, Zinder C. The burden of illness of cancer: economic cost and quality of life. Annu Rev Public Health. 2001;22:91\u2013113.","journal-title":"Annu Rev Public Health"},{"key":"275_CR2","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1093\/jnci\/djn103","volume":"100","author":"KR Yabroff","year":"2008","unstructured":"Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, Brown ML. Cost of care for elderly cancer patients in the United States. J Natl Canc Inst. 2008;100:630\u201341.","journal-title":"J Natl Canc Inst"},{"key":"275_CR3","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/jnci\/djk013","volume":"99","author":"LG Kessler","year":"2007","unstructured":"Kessler LG, Ramsey SD. The forest and the trees: the human costs of cancer. J Natl Canc Inst. 2007;99:2\u20133.","journal-title":"J Natl Canc Inst"},{"key":"275_CR4","first-page":"2213","volume-title":"Cancer principles and practice of oncology","author":"FA Greco","year":"2005","unstructured":"Greco FA, Hainsworth JD. Cancer of unknown primary site. In: de Vita VT, editor. Cancer principles and practice of oncology. 7th ed. Philadelphia: Lippincott, Williams & Wilkins; 2005. p. 2213\u201336.","edition":"7"},{"key":"275_CR5","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.anndiagpath.2004.12.003","volume":"9","author":"N Al-Brahim","year":"2005","unstructured":"Al-Brahim N, Ross C, Carter B, Chorneyko K. The value of postmortem examination in cases of metastases of unknown origin \u221220\u00a0years retrospective data from a tertiary care center. Ann Diagn Pathol. 2005;9:77\u201380.","journal-title":"Ann Diagn Pathol"},{"key":"275_CR6","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1016\/S0959-8049(03)00547-1","volume":"39","author":"N Pavlidis","year":"2003","unstructured":"Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990\u20132005.","journal-title":"Eur J Cancer"},{"key":"275_CR7","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1159\/000089260","volume":"26","author":"R Molina","year":"2005","unstructured":"Molina R, Barak V, van Dalen A, Duffy MJ, Einarsson R, Gion M, et al. Tumor markers in breast cancer. European Group on Tumor Markers recommendations. Tumor Biol. 2005;26:281\u201393.","journal-title":"Tumor Biol"},{"key":"275_CR8","doi-asserted-by":"crossref","first-page":"1348","DOI":"10.1016\/j.ejca.2007.03.021","volume":"43","author":"MJ Duffy","year":"2007","unstructured":"Duffy MJ, van Dalen A, Haglund C, Hansson L, Holinski-Feder R, Klapdor R, et al. Tumour markers in colorectal cancer: European Group on Tumor Markers (EGTM) guidelines for clinical use. Eur J Cancer. 2007;43:1348\u201360.","journal-title":"Eur J Cancer"},{"key":"275_CR9","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1111\/j.1525-1438.2005.00130.x","volume":"15","author":"MJ Duffy","year":"2005","unstructured":"Duffy MJ, Bonfrer JM, Kulpas J, Rustin GJ, Soletormos G, Torre GC, et al. CA 125 in ovarian cancer: European group on tumor markers guidelines for clinical use. Int J Gynecol Canc. 2005;15:679\u201391.","journal-title":"Int J Gynecol Canc"},{"key":"275_CR10","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1373\/clinchem.2008.105601","volume":"54","author":"CM Sturgeon","year":"2008","unstructured":"Sturgeon CM, Duffy MJ, Stenman UH, Lilja H, Brunner N, Chan DW, et al. National Academy of Clinical Biochemistry laboratory medicine practice guidelines for use of tumor markers in testicular, prostate, colorectal, breast, and ovarian cancers. Clin Chem. 2008;54:11\u201379.","journal-title":"Clin Chem"},{"key":"275_CR11","doi-asserted-by":"crossref","first-page":"5287","DOI":"10.1200\/JCO.2007.14.2364","volume":"25","author":"L Harris","year":"2007","unstructured":"Harris L, Fritsche H, Mennel R, Norton L, Ravdin P, Taube S, et al. American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol. 2007;25:5287\u2013312.","journal-title":"J Clin Oncol"},{"key":"275_CR12","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1093\/jnci\/djh081","volume":"96","author":"GJ Rustin","year":"2004","unstructured":"Rustin GJ, Quinn M, Thigpen T, du Bois A, Pujade-Lauraine E, Jakobsen A, et al. New guidelines to evaluate the response to treatment in solid tumors (ovarian cancer). J Natl Canc Inst. 2004;96:487\u20138.","journal-title":"J Natl Canc Inst"},{"key":"275_CR13","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/annonc\/mdp332","volume":"21","author":"MH Duffy","year":"2010","unstructured":"Duffy MH, Sturgeon C, Lamer R, Haglund C, Holubec VL, Klapdor R, et al. Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report. Ann Oncol. 2010;21:441\u20137.","journal-title":"Ann Oncol"},{"key":"275_CR14","doi-asserted-by":"crossref","first-page":"5313","DOI":"10.1200\/JCO.2006.08.2644","volume":"24","author":"GY Locker","year":"2006","unstructured":"Locker GY, Hamilton S, Harris J, Jessup JM, Kemeny N, Macdonald JS, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313\u201327.","journal-title":"J Clin Oncol"},{"key":"275_CR15","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1159\/000073846","volume":"24","author":"R Molina","year":"2003","unstructured":"Molina R, Filella X, Lejarcegui JA, Pahisa A, Torne A, Rovirosa B, et al. Prospective evaluation of squamous cell carcinoma and carcinoembryonic antigen as prognostic factors in patients with cervical cancer. Tumor Biol. 2003;24:156\u201364.","journal-title":"Tumor Biol"},{"key":"275_CR16","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/BF00690183","volume":"36","author":"R Molina","year":"1995","unstructured":"Molina R, Zanon G, Filella X, Moreno F, Daniels M, Zanon G, et al. Use of serial carcinoembryonic antigen and CA 15.3 assays in detecting relapses in breast cancer patients. Br Canc Res Treat. 1995;36:41\u20138.","journal-title":"Br Canc Res Treat"},{"key":"275_CR17","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1007\/s10620-006-9166-5","volume":"51","author":"S Choi","year":"2006","unstructured":"Choi S, Jang J, Lee J, Roh MH, Kim MC, Lee WS, et al. Role of serum tumor markers in monitoring for recurrence of gastric cancer following radical gastrectomy. Dig Dis Sci. 2006;51:2081\u20136.","journal-title":"Dig Dis Sci"},{"key":"275_CR18","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"SH Swerdlow","year":"2008","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stelin H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th ed. Geneva: World Health Organization; 2008.","edition":"4"},{"key":"275_CR19","doi-asserted-by":"crossref","first-page":"1486","DOI":"10.1378\/chest.104.5.1486","volume":"104","author":"M Maurel","year":"1993","unstructured":"Maurel M, Arustova M, Stansy B, Light RW. Incidence of pleural effusion in a well-defined region: epidemiology study in central Bohemia. Chest. 1993;104:1486\u20139.","journal-title":"Chest"},{"key":"275_CR20","first-page":"2586","volume-title":"Cancer principles and practice of oncology","author":"HI Pass","year":"1997","unstructured":"Pass HI. Malignant pleural and pericardial effusions. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven; 1997. p. 2586\u201398.","edition":"5"},{"key":"275_CR21","first-page":"2598","volume-title":"Cancer principles and practice of oncology","author":"FM Maringola","year":"1997","unstructured":"Maringola FM, Schwartzentruber DJ. Malignant ascites. In: De Vita VT, Hellman S, Rosenberg SA, editors. Cancer principles and practice of oncology. 5th ed. Philadelphia: Lippincott-Raven; 1997. p. 2598\u2013606.","edition":"5"},{"key":"275_CR22","doi-asserted-by":"crossref","first-page":"4679","DOI":"10.1200\/JCO.2002.04.019","volume":"20","author":"S Culine","year":"2002","unstructured":"Culine S, Kramar A, Saghatchion M, Bugat R, Lesimple T, Latholary A, et al. Development and validation of a prognostic model to predict the length of survival in patients with carcinomas of an unknown primary site. J Clin Oncol. 2002;20:4679\u201383.","journal-title":"J Clin Oncol"},{"key":"275_CR23","first-page":"297","volume":"24","author":"AJ Wouw Van de","year":"2004","unstructured":"Van de Wouw AJ, Jansen RLH, Griffionen AW, Hillen HFP. Clinical and immunohistochemical analysis of patients with unknown primary tumor. A search for prognostic factors in UPT. Anticancer Res. 2004;24:297\u2013302.","journal-title":"Anticancer Res"},{"key":"275_CR24","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1159\/000181180","volume":"29","author":"R Molina","year":"2008","unstructured":"Molina R, Auge JM, Bosch X, Escudero JM, Marrades R, Vi\u00f1olas N, et al. Mucins CA 125, CA 199, CA 15.3, and TAG 72.3 as tumor markers in patients with lung cancer: comparison with CYFRA 21-1, CEA, SCC and NSE. Tumor Biol. 2008;29:371\u201380.","journal-title":"Tumor Biol"},{"key":"275_CR25","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1002\/jso.20604","volume":"95","author":"N Duraker","year":"2007","unstructured":"Duraker N, Hot S, Polat Y, H\u00f6bek N, Gen\u00e7ler N, Urhan N. CEA, CA 19.9, and CA 125 in the differential diagnosis of benign and malignant pancreatic diseases with or without jaundice. J Surg Oncol. 2007;95:142\u20137.","journal-title":"J Surg Oncol"},{"key":"275_CR26","first-page":"219","volume":"51","author":"J Trape","year":"2005","unstructured":"Trape J, Molina R, Sant F. Clinical evaluation of the simultaneous determination of tumor markers in fluid and serum and their ratio in the differential diagnosis of serous effusions. Tumor Biol. 2005;51:219\u201322.","journal-title":"Tumor Biol"},{"key":"275_CR27","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1159\/000224628","volume":"30","author":"R Molina","year":"2009","unstructured":"Molina R, Auge JM, Bosch X, Escudero JM, Vi\u00f1olas N, Marrades R, et al. Usefulness of serum tumor markers, including progastrin-releasing peptide in patients with lung cancer: correlation with histology. Tumor Biol. 2009;30:121\u20139.","journal-title":"Tumor Biol"},{"key":"275_CR28","first-page":"271","volume":"79","author":"X Filella","year":"1992","unstructured":"Filella X, Molina R, Jo J, Bedini JL, Joseph J, Ballesta AM. Tumor associated glycoprotein-72 (TAG-72) levels in patients with non-malignant and malignant diseases. Bull Cancer. 1992;79:271\u20137.","journal-title":"Bull Cancer"},{"key":"275_CR29","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/clinchem\/36.2.251","volume":"36","author":"R Molina","year":"1990","unstructured":"Molina R, Filella X, Torres MD, Ballesta AM, Mengual P, Cases A, Balague A. SCC antigen measured in malignant and non malignant diseases. Clin Chem. 1990;36:251\u20134.","journal-title":"Clin Chem"},{"key":"275_CR30","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/clinchem\/37.8.1379","volume":"37","author":"R Molina","year":"1991","unstructured":"Molina R, Filella X, Bruix J, Mengual PJ, Bosch J, Calvet X, et al. Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem. 1991;37:1379\u201383.","journal-title":"Clin Chem"},{"key":"275_CR31","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s10620-007-9825-1","volume":"53","author":"T Ohtsuka","year":"2008","unstructured":"Ohtsuka T, Sato S, Kitajima Y. False positive findings for tumors markers after curative gastrectomy for gastric cancer. Dig Dis Sci. 2008;53:73\u20139.","journal-title":"Dig Dis Sci"},{"key":"275_CR32","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1159\/000186247","volume":"57","author":"A Cases","year":"1991","unstructured":"Cases A, Filella X, Molina R, Ballesta AM, Lopez-Revert JL, Revert L. Tumor markers in chronic renal failure and hemodialysis patients. Nephron. 1991;57:183\u20136.","journal-title":"Nephron"},{"key":"275_CR33","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1159\/000082919","volume":"67","author":"A Symeonides","year":"2004","unstructured":"Symeonides A, Kouraklis-Symeonides A, Apostolopoulos D, Arvanitopoulou E, Giannakoulas N, Vassilakos P, et al. Increased serum CA 15.3 levels in patients with megaloblastic anemia due to vitamin B12 deficiency. Oncology. 2004;67:359\u201367.","journal-title":"Oncology"},{"key":"275_CR34","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1378\/chest.126.6.1757","volume":"126","author":"JM Porcel","year":"2004","unstructured":"Porcel JM, Vives M, Esquerda A, Salud A, Perez B, Rodriguez-Panadero F. Use of a panel of tumor markers (carcinoembryonic antigen, cancer antigen 125, carbohydrate antigen 15-3, and cytokeratin 19 fragments) in pleural fluid for the differential diagnosis of benign and malignant effusions. Chest. 2004;126:1757\u201363.","journal-title":"Chest"},{"key":"275_CR35","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1038\/sj.bjc.6690807","volume":"81","author":"M Mi\u00e9doug\u00e9","year":"1999","unstructured":"Mi\u00e9doug\u00e9 M, Rouzaud P, Salama G, Pujazon MC, Vincent C, Mauduyl MA, et al. Evaluation of seven tumour markers in pleural fluid for the diagnosis of malignant effusions. Br J Cancer. 1999;81:1059\u201361.","journal-title":"Br J Cancer"},{"key":"275_CR36","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1038\/jid.2008.71","volume":"128","author":"RG El-Rachkidy","year":"2008","unstructured":"El-Rachkidy RG, Young HS, Griffiths CE, Camp RD. Humoral autoimmune responses to the squamous cell carcinoma antigen protein family in psoriasis. J Invest Dermatol. 2008;128:2219\u201324.","journal-title":"J Invest Dermatol"},{"key":"275_CR37","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1159\/000210385","volume":"150","author":"Y Yamane","year":"2009","unstructured":"Yamane Y, Moriyama K, Yasuda C, Miyata S, Aihara M, Ikezawa Z, et al. New horny layer marker proteins for evaluating skin condition in atopic dermatitis. Int Arch Allergy Immunol. 2009;150:89\u2013101.","journal-title":"Int Arch Allergy Immunol"},{"key":"275_CR38","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1159\/000072332","volume":"65","author":"Y Adachi","year":"2003","unstructured":"Adachi Y, Tsuchihashi J, Shiraishi N, Yasuda K, Etoh T, Kitano S. AFP-producing gastric carcinoma: multivariate analysis of prognostic factors in 270 patients. Oncology. 2003;65:95\u2013101.","journal-title":"Oncology"},{"key":"275_CR39","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1007\/s10120-003-0240-9","volume":"6","author":"Y Takahashi","year":"2003","unstructured":"Takahashi Y, Takeuchi T, Sakamoto J, Touge T, Mai M, Ohkura H, et al. The usefulness of CEA and\/or CA19-9 in monitoring for recurrence in gastric cancer patients: a prospective clinical study. Gastric Cancer. 2003;6:142\u20135.","journal-title":"Gastric Cancer"},{"key":"275_CR40","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00432-006-0110-z","volume":"132","author":"K Yonemori","year":"2006","unstructured":"Yonemori K, Ando M, Shibata T, Katsumata N, Matsumoto K, Yamanaka Y, et al. Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy. J Canc Res Clin Oncol. 2006;132:635\u201342.","journal-title":"J Canc Res Clin Oncol"},{"key":"275_CR41","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1016\/S0959-8049(96)00346-2","volume":"32","author":"DC Currow","year":"1996","unstructured":"Currow DC, Findlay M, Cox K, Harnette PR. Elevated germ cell markers in carcinoma of uncertain primary site do not predict response to platinum based chemotherapy. Eur J Cancer. 1996;32:2357\u20139.","journal-title":"Eur J Cancer"},{"key":"275_CR42","first-page":"25","volume":"8","author":"M Milovic","year":"2002","unstructured":"Milovic M, Popov I, Jelic S. Tumor markers in metastatic disease from cancer of unknown primary origin. Med Sci Mon. 2002;8:25\u201330.","journal-title":"Med Sci Mon"},{"key":"275_CR43","doi-asserted-by":"crossref","first-page":"1776","DOI":"10.1002\/cncr.20202","volume":"100","author":"GR Varadhachary","year":"2004","unstructured":"Varadhachary GR, Abbruzzesse JL, Lenzi R. Diagnostic strategies for unknown primary cancer. Cancer. 2004;100:1776\u201385.","journal-title":"Cancer"},{"key":"275_CR44","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jbspin.2006.05.009","volume":"74","author":"Cl Destombe","year":"2007","unstructured":"Destombe Cl, Botton E, Le Gal G, Roudaut A, Jousse-Joulin S, Devauchelle-Pensec V, Saraux A. Investigations for bone metastases from an unknown primary. Joint Bone Spine. 2007;74:85\u20139.","journal-title":"Joint Bone Spine"},{"key":"275_CR45","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1378\/chest.126.6.1721","volume":"126","author":"RW Light","year":"2004","unstructured":"Light RW. Tumor markers in undiagnosed pleural effusions. Chest. 2004;126:1721\u20132.","journal-title":"Chest"},{"key":"275_CR46","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1378\/chest.128.4.2298","volume":"128","author":"JH Lee","year":"2005","unstructured":"Lee JH, Chang JH. Diagnostic utility of serum and pleural fluid carcinoembryonic antigen, neuron-specific enolase, and cytokeratin 19 fragments in patients with effusions from primary lung cancer. Chest. 2005;128:2298\u2013303.","journal-title":"Chest"},{"key":"275_CR47","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1158\/1055-9965.EPI-04-0624","volume":"14","author":"Z Amoura","year":"2005","unstructured":"Amoura Z, Duhaut P, Huong DL, Wechsler B, Costedoat-Charlumeau N, Frances C, et al. Tumor antigen markers for the detection of solid cancers in inflammatory myopathies. Canc Epidemiol Biomarkers Prev. 2005;14:1279\u201382.","journal-title":"Canc Epidemiol Biomarkers Prev"}],"container-title":["Tumor Biology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-011-0275-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13277-011-0275-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13277-011-0275-1","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,28]],"date-time":"2020-06-28T12:31:41Z","timestamp":1593347501000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13277-011-0275-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,12,9]]},"references-count":47,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,4]]}},"alternative-id":["275"],"URL":"https:\/\/doi.org\/10.1007\/s13277-011-0275-1","relation":{},"ISSN":["1010-4283","1423-0380"],"issn-type":[{"value":"1010-4283","type":"print"},{"value":"1423-0380","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,12,9]]}}}